Evidence map›Paper›PMID 29544527›Full record

ReviewAlzheimer's research & therapy2018

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation.

Charlotte E Teunissen, Markus Otto, Sebastiaan Engelborghs, Sanna-Kaisa Herukka, Sylvain Lehmann, Piotr Lewczuk, Alberto Lleó, Armand Perret-Liaudet, Hayrettin Tumani, Martin R Turner and 5 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Alzheimer's research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Plasma protein risk scores for mild cognitive impairment and Alzheimer's disease in the Framingham heart study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Biomarkers for dementia in Latin American countries: Gaps and opportunities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Charlotte E TeunissenNeurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. c.teunissen@vumc.nl.ORCID 0000-0002-4061-0837
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Sebastiaan EngelborghsReference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium.
Sanna-Kaisa HerukkaDepartment of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland.
Sylvain LehmannUniversité de Montpellier, University Hospital, INSERM U1183, Montpellier, France.
Piotr LewczukDepartment of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Erlangen, Germany.
Alberto LleóMemory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau, Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Armand Perret-LiaudetNeurobiology Laboratory, Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Lyon, France.
Hayrettin TumaniDepartment of Neurology, CSF Laboratory, MS Outpatient Unit, University Hospital of Ulm, Ulm, Germany.
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Marcel M VerbeekRadboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Departments of Neurology and Laboratory Medicine, Radboud Alzheimer Centre, Nijmegen, The Netherlands.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University, Goettingen, Germany.
Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Lucilla ParnettiCenter for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy.
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Funding

Medical Research Council MR/K01014X/1Motor Neurone Disease Association TURNER/JAN13/944-795Motor Neurone Disease Association TURNER/OCT15/972-797Motor Neurone Disease Association TURNER/OCT18/989-797
6 · The paper itself

Abstract

Body fluid biomarkers have great potential for different clinical purposes, including diagnosis, prognosis, patient stratification and treatment effect monitoring. This is exemplified by current use of several excellent biomarkers, such as the Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, anti-neuromyelitis optica antibodies and blood neurofilament light. We still, however, have a strong need for additional biomarkers and several gaps in their development and implementation should be filled. Examples of such gaps are i) limited knowledge of the causes of neurological diseases, and thus hypotheses about the best biomarkers to detect subclinical stages of these diseases; ii) the limited success translating discoveries obtained by e.g. initial mass spectrometry proteomic low-throughput studies into immunoassays for widespread clinical implementation; iii) lack of interaction among all stakeholders to optimise and adapt study designs throughout the biomarker development process to medical needs, which may change during the long period needed for biomarker development.The Society for CSF Analysis and Clinical Neurochemistry (established in 2015) has been founded as a concerted follow-up of large standardisation projects, including BIOMARKAPD and SOPHIA, and the BioMS-consortium.The main aims of the CSF society are to exchange high level international scientific experience, to facilitate the incorporation of CSF diagnostics into clinical practice and to give advice on inclusion of CSF analysis into clinical guidelines. The society has a broad scope, as its vision is that the gaps in development and implementation of biomarkers are shared among almost all neurological diseases and thus they can benefit from the activities of the society.

Indexed as

NeurochemistryAlzheimer DiseaseBiomarkersHumansBiomarkersAssay developmentBiomarker discoveryBody fluidsCerebrospinal fluidClinical implementationEducation BiomarkersNeurologySociety

Identifiers

PMID29544527
PMCPMC5855933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.